Melanoma in situ of eyelid, including canthus
ICD-10 D03.1 is a billable code used to indicate a diagnosis of melanoma in situ of eyelid, including canthus.
Melanoma in situ of the eyelid, including the canthus, is a localized form of skin cancer characterized by the presence of atypical melanocytes confined to the epidermis. This condition is considered a precursor to invasive melanoma and is often detected during routine skin examinations or due to changes in the appearance of the eyelid. Clinically, it may present as a pigmented lesion, which can vary in color from brown to black, or as an amelanotic lesion that appears pink or flesh-colored. The eyelid's thin skin and high vascularity can lead to rapid progression if left untreated. Surveillance protocols typically involve regular dermatological evaluations, with recommendations for excisional biopsy to confirm diagnosis and assess margins. The risk of progression to invasive melanoma is significant, particularly in cases where the lesion is not adequately excised. Early detection and treatment are crucial to prevent metastasis and preserve eyelid function and aesthetics.
Detailed descriptions of the lesion, including size, color, and location, along with biopsy results.
Diagnosis and management of pigmented lesions on the eyelid, follow-up after excision.
Ensure clear documentation of margins and any additional treatments or referrals.
Documentation of visual acuity, eyelid function, and any impact on vision.
Management of eyelid lesions affecting vision or eyelid function.
Coordination with dermatology for comprehensive care and documentation of surgical interventions.
Used when excising a melanoma in situ from the eyelid.
Document the size of the lesion and margins.
Ensure coordination between dermatology and ophthalmology for optimal care.
Coding melanoma in situ accurately is crucial for tracking treatment outcomes, understanding progression risks, and ensuring appropriate reimbursement for care provided.
